{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:52:48Z","timestamp":1777953168413,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.critrevonc.2024.104372","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:54:38Z","timestamp":1714114478000},"page":"104372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"198","author":[{"given":"Wei","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zixiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-0487","authenticated-orcid":false,"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10272","key":"10.1016\/j.critrevonc.2024.104372_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104372_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejca.2022.02.030","article-title":"Systemic therapy for pre-treated malignant mesothelioma: a systematic review, meta-analysis and network meta-analysis of randomised controlled trials","volume":"166","author":"Banna","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"142","key":"10.1016\/j.critrevonc.2024.104372_bib3","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur. Respir. Rev. Off. J. Eur. Respir. Soc."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104372_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bill\u00e9","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104372_bib5","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","article-title":"Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications","volume":"10","author":"Blum","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2024.104372_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks","volume":"105","author":"Brignardello-Petersen","year":"2019","journal-title":"J. Clin. Epidemiol."},{"issue":"17_suppl","key":"10.1016\/j.critrevonc.2024.104372_bib7","doi-asserted-by":"crossref","first-page":"LBA8505","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA8505","article-title":"IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and IFCT trial","volume":"41","author":"Chu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib8","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","article-title":"Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma","volume":"128","author":"Demirag","year":"2005","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104372_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jrsm.1085","article-title":"Assessing key assumptions of network meta-analysis: a review of methods","volume":"4","author":"Donegan","year":"2013","journal-title":"Res. Synth. Methods"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2024.104372_bib10","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2021.39.15_suppl.8507","article-title":"A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma","volume":"39","author":"Fennell","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104372_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","article-title":"Immunotherapy approaches for malignant pleural mesothelioma","volume":"19","author":"Fennell","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104372_bib12","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104372_bib13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104372_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (Alimta)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104372_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/joim.12690","article-title":"Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis","volume":"283","author":"Heldin","year":"2018","journal-title":"J. Intern Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"7414","key":"10.1016\/j.critrevonc.2024.104372_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin. Res. Ed. )"},{"key":"10.1016\/j.critrevonc.2024.104372_bib19","article-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins JPT","year":"2010","journal-title":"Int. Coach. Psychol. Rev."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104372_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104372_bib21","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104372_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(22)00061-4","article-title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","volume":"23","author":"Kindler","year":"2022","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104372_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104372_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104372_bib25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2014.06.008","article-title":"Randomized phase II trial of pemetrexed\/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma","volume":"85","author":"Krug","year":"2014","journal-title":"Lung Cancer"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104372_bib26","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104372_bib27","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Masood","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104372_bib29","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib30","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","article-title":"Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time","volume":"29","author":"Pasello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104372_bib32","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104372_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(","volume":"33","author":"Popat","year":"2022","journal-title":"\u2606). Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104372_bib34","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European thoracic oncology platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib35","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reyni\u00e8s","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104372_bib36","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104372_bib37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104372_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104372_bib39","first-page":"l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ Clin. Res. Ed."},{"key":"10.1016\/j.critrevonc.2024.104372_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase plus first-line chemotherapy in patients with nonepithelioid pleural mesothelioma: the ATOMIC-meso randomized clinical trial","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104372_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104372_bib42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104372_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010182","article-title":"Salvage therapy for relapsed malignant pleural mesothelioma: a systematic review and network meta-analysis","volume":"14","author":"Tsai","year":"2021","journal-title":"Cancers"},{"issue":"28","key":"10.1016\/j.critrevonc.2024.104372_bib44","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II trial of cediranib in combination With Cisplatin and pemetrexed in chemotherapy-na\u00efve patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104372_bib45","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options","volume":"40","author":"Tsao","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104372_bib46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res. Synth. Methods"},{"issue":"14","key":"10.1016\/j.critrevonc.2024.104372_bib47","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10026","key":"10.1016\/j.critrevonc.2024.104372_bib48","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282400115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282400115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T22:46:59Z","timestamp":1717022819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282400115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":48,"alternative-id":["S104084282400115X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104372","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of first-line and salvage therapies for unresectable malignant mesothelioma: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104372"}}